Pfizer (PFE) Earnings Date & Reports

Pfizer delivered Q1 2026 revenues of $14.5 billion, a 5% reported increase or 2% operational growth year-over-year from $13.7 billion, exceeding analyst consensus of approximately $13.8-13.9 billion. Adjusted diluted earnings per share (EPS) reached $0.75, beating expectations of $0.72 while down 18% from $0.92 last year; reported diluted EPS was $0.47, down 10% from $0.52. These beats stemmed from robust non-COVID performance, with underlying business revenues up 7% operationally and launched/acquired products up 22%.

Key drivers included Padcev (+39% operational, boosted by market share gains), oncology biosimilars (+52%), Nurtec ODT/Vydura (+41%), Lorbrena (+32%), and Xeljanz (+34%). Eliquis grew 8% amid demand offset by generics. COVID declines weighed on totals, but operational efficiency shone: cost of sales rose to 24.6% of revenues (from 20.7%), R&D expenses increased 12% to $2.49 billion (oncology/obesity focus), and SI&A (selling, informational, and administrative) expenses fell 4% operationally to $2.96 billion. Guidance for full-year 2026 was reaffirmed unchanged, signaling confidence despite no upward revision.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across diverse portfolios. Explore the AI Screener today to streamline your research process.

Market Reaction and Investor Sentiment

Pfizer shares closed up 0.6% at $26.44 on May 5, 2026, after trading as high as $26.74 intraday, with premarket gains around 0.7% following the pre-open release. Volume exceeded 48 million shares, reflecting interest. Sentiment was mixed: beats on revenue and EPS were positives, but unchanged 2026 guidance—below some Street expectations for raises—tempered enthusiasm. Analysts noted "mild" results unlikely to sway skeptics amid patent pressures, yet CEO Albert Bourla's emphasis on pipeline momentum in oncology and obesity supported modest optimism. Overall, the reaction underscores focus on execution beyond short-term beats.

Forward Outlook and Key Factors to Monitor

Pfizer reaffirmed its 2026 guidance, projecting revenues of $59.5-62.5 billion (roughly flat to slightly down from 2025's $62.6 billion) and adjusted diluted EPS of $2.80-3.00, incorporating $1.5 billion in LOE impacts, no further business development beyond May 5, stable exchange rates, and no share repurchases. This assumes mid-70s adjusted gross margins, disciplined SI&A at $12.5-13 billion, and R&D around $10.8-11 billion.

Investors should watch pipeline catalysts: ~20 pivotal trials in 2026, including obesity programs, Lyme vaccine submissions, and oncology readouts like Elrexfio and Talzenna combos. Regulatory milestones, such as FDA priority reviews for Padcev and Hympavzi expansions, could drive uptake. Recent deals like Sciwind collaboration for ecnoglutide (up to $495 million milestones) and ViiV stake sale ($1.875 billion) bolster BD capacity at ~$7 billion.

Cost trends remain key: ongoing productivity savings offset R&D hikes, with operating cash flow at $2.6 billion in Q1 supporting $2.4 billion dividends ($0.43/share). Balance sheet de-levering (leverage ~2.8x) preserves flexibility. Broader dynamics include generic erosion on Eliquis/Vyndaqel, biosimilar competition, and macro factors like tariffs. Long-term, Pfizer eyes high single-digit revenue CAGR post-2028 via pipeline leadership.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations